Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Georgetown University
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07645326CT.gov RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | — | Not Yet Recruiting | — | — | — |
NCT07590934CT.gov Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07365995CT.gov A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07287150CT.gov A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT07268794CT.gov CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer | — | Not Yet Recruiting | — | — | — |
NCT07213674CT.gov A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06392841CT.gov Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations | — | Withdrawn | — | — | — |
NCT06764485CT.gov A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT06734130CT.gov Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT06661122CT.gov A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy and Docetaxel in Routine Medical Care for Japanese Men With Low Volume Metastatic Hormone-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
Show 35 more trialsShow fewer
NCT06520345CT.gov The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | — | Recruiting | — | — | — |
NCT06480110CT.gov Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT06320067CT.gov A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06430411CT.gov Outcomes of Local Treatment for Oligometastatic Prostate Cancer Diagnosed Using PSMA PET Imaging: OLIGOMET Study | — | Not Yet Recruiting | — | — | — |
NCT06387056CT.gov Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) | — | Recruiting | — | — | — |
NCT05762536CT.gov Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC | — | Recruiting | — | — | — |
NCT07112209CT.gov Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer | — | Enrolling By Invitation | — | — | — |
NCT05701007CT.gov Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland | — | Completed | — | — | — |
NCT05005728CT.gov XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04629781CT.gov Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC | — | Terminated | — | — | — |
NCT04666129CT.gov Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT04603833CT.gov A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC | — | Unknown | — | — | — |
NCT04140526CT.gov Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC | — | Active Not Recruiting | — | — | — |
NCT04586543CT.gov Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | — | Unknown | — | — | — |
NCT04343885CT.gov In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT04028388CT.gov ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT03517969CT.gov M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03951831CT.gov REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03903835CT.gov ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03582475CT.gov Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate | — | Active Not Recruiting | — | — | — |
NCT03218826CT.gov PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT03442556CT.gov Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency | — | Terminated | — | — | — |
NCT03696186CT.gov Selective Treatment According to Molecular Subtype of Prostate Cancer | — | Unknown | — | — | — |
NCT03230734CT.gov Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02913196CT.gov Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC | — | Completed | — | — | — |
NCT02861573CT.gov Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) | — | Recruiting | — | — | — |
NCT02740985CT.gov A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies | — | Completed | — | — | — |
NCT02565901CT.gov Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02044354CT.gov Patient Preference Between Cabazitaxel and Docetaxel in Metastatic Castrate-resistant Prostate Cancer | — | Completed | — | — | — |
NCT02036060CT.gov Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer. | — | Completed | — | — | — |
NCT02105675CT.gov Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01155791CT.gov Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT00439270CT.gov Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00541281CT.gov Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer | — | Completed | — | — | — |
NCT00213694CT.gov PROSTACOX : Metastatic Prostate Chemotherapy | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metastatic Prostate Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Docetaxel (this asset) | Georgetown University | P3 | BB · 64 |
| AXUMIN | VA Greater Los Angeles Healthcare System | P4 | BBB |
| Leuporelin | Mayo Clinic | P4 | BBB |
| Abiraterone | Mayo Clinic | P4 | BB |
| Prednisone | Mayo Clinic | P4 | BB |
| Pembrolizumab | CuraCell TX AB | P2 | BB |
| Cabazitaxel | AstraZeneca | P4 | BB |
| Degarelix | Praful Ravi, MB BCHir, MRCP | P3 | BB |
| Carboplatin | Case Comprehensive Cancer Center | P3 | BB |
+42 more in the Metastatic Prostate Carcinoma cohort
Other indications for Docetaxel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Prostate Neoplasm | — | P4 | BBB · 73 |
| Pancreatic Adenocarcinoma | — | P2 | BBB · 72 |
| Cancer Of Unknown Primary Site | — | P2 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Docetaxel in Metastatic Prostate Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/docetaxel-metastatic-prostate-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →